TY - JOUR
T1 - Risk Factors for Acute Rejection After Deceased Donor Kidney Transplantation in China
AU - Fu, Q.
AU - Zhang, H.
AU - Nie, W.
AU - Deng, R.
AU - Li, J.
AU - Xiong, Y.
AU - Dai, Y.
AU - Liu, L.
AU - Yuan, X.
AU - He, X.
AU - Wang, C.
N1 - Funding Information:
This work was supported by the Natural Science Foundation of China (Grant nos. 81670680 , 81300623 , and 81700655 ), the Science and Technology Planning Project of Guangdong Province, China (Grant nos. 2015B020226002, 2014B020212006, 2013B021800292, and 2014A020212719), the Natural Science Foundation of Guangdong Province (Grant nos. 2015A030313135 and 2014A030313022 ), the Science and Technology Program of Guangzhou, China (Grant no. 2014Y2-00114), and the Guangdong Provincial Key Laboratory on Organ Donation and Transplant Immunology (Grant no. 2013A 061401007).We thank Fangchao Yu for his meticulous work on collecting clinical data.
Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2018/10
Y1 - 2018/10
N2 - Objectives: This study aimed to identify the potential risk factors of acute rejection after deceased donor kidney transplantation in China. Methods: Adult kidney transplantations from deceased donors in our center from February 2004 to December 2015 were enrolled for retrospective analysis. All deceased donations complied with China's Organ Donation Program. No organs from executed prisoners were used. The incidence of clinical and biopsy-proved acute rejection was assessed with the Kaplan-Meier method, and the Cox proportional hazard model was used for multivariate analysis. Results: One-year, 2-year, 3-year and 5-year incidences of acute rejection were 12.4%, 14.2%, 14.8%, and 17.1%, respectively. Multivariate analysis demonstrated that longer pre-transplant dialysis duration (hazard ratio [HR] 1.009 per month; 95% confidence interval, 1.003–1.015; P =.003), positive pre-transplant panel reactive antibody (PRA) (positive vs negative HR 3.266; 1.570–6.793; P =.023), and increasing HLA mismatches (≥4 vs < 4 HR 2.136; 1.022–4.465; P =.044) increased the risk of acute rejection, while tacrolimus decreased acute rejection risk compared to cyclosporine (HR 0.317; 0.111–0.906; P =.032). Conclusion: Longer pre-transplant dialysis duration, HLA mismatch, and positive pre-transplant PRA increase the risk of acute rejection, while tacrolimus helps prevent acute rejection compared to cyclosporine in deceased donor kidney transplantation.
AB - Objectives: This study aimed to identify the potential risk factors of acute rejection after deceased donor kidney transplantation in China. Methods: Adult kidney transplantations from deceased donors in our center from February 2004 to December 2015 were enrolled for retrospective analysis. All deceased donations complied with China's Organ Donation Program. No organs from executed prisoners were used. The incidence of clinical and biopsy-proved acute rejection was assessed with the Kaplan-Meier method, and the Cox proportional hazard model was used for multivariate analysis. Results: One-year, 2-year, 3-year and 5-year incidences of acute rejection were 12.4%, 14.2%, 14.8%, and 17.1%, respectively. Multivariate analysis demonstrated that longer pre-transplant dialysis duration (hazard ratio [HR] 1.009 per month; 95% confidence interval, 1.003–1.015; P =.003), positive pre-transplant panel reactive antibody (PRA) (positive vs negative HR 3.266; 1.570–6.793; P =.023), and increasing HLA mismatches (≥4 vs < 4 HR 2.136; 1.022–4.465; P =.044) increased the risk of acute rejection, while tacrolimus decreased acute rejection risk compared to cyclosporine (HR 0.317; 0.111–0.906; P =.032). Conclusion: Longer pre-transplant dialysis duration, HLA mismatch, and positive pre-transplant PRA increase the risk of acute rejection, while tacrolimus helps prevent acute rejection compared to cyclosporine in deceased donor kidney transplantation.
UR - http://www.scopus.com/inward/record.url?scp=85054429493&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054429493&partnerID=8YFLogxK
U2 - 10.1016/j.transproceed.2018.03.063
DO - 10.1016/j.transproceed.2018.03.063
M3 - Article
C2 - 30316380
AN - SCOPUS:85054429493
SN - 0041-1345
VL - 50
SP - 2465
EP - 2468
JO - Transplantation Proceedings
JF - Transplantation Proceedings
IS - 8
ER -